hotspot -WSS

hotspot

author：entertainment 2025-09-30 14:59:09 - browse：36922

Element Biosciences exterior -- biotech coverage from STAT — Element Biosciences exterior Element Biosciences

SAN DIEGO — Companies racing to read the genome accurately, quickly, and affordably have hit a snag recently, with several firms reporting that their growth has slowed, stalled, or reversed. Upstart Element Biosciences is hoping it can succeed despite the challenging market conditions.

The San Diego firm launched a $290,000 sequencer, dubbed Aviti, in March 2022 and now has 150 instruments installed in more than 25 countries, according to a sales update Element shared with STAT. The modest growth comes at a time when some other players are struggling. Singular Genomics announced layoffs of 20% of its workforce earlier this year after the lackluster launch of its own sequencer. And Pacific Biosciences recently laid off nearly 200 employees after reporting disappointing first-quarter sales.

Element still has a long way to go in its bid to rival Illumina, a genomics giant that dominates 80% of the sequencing market and has more than 23,000 instruments in use around the world. That includes the NextSeq 2000, a $335,000 sequencer with a similar output to Aviti. Element is betting its blend of accuracy and a more moderate price point can help it carve out a niche of academic and biopharma customers.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Biogen joins immunology wave with $1.15 billion acquisition of HI

WSS

STAT Virtual Event: Putting AI to the Test

STAT Virtual Event: Putting AI to the Test

Ukraine and a new approach to mental health in war

Biotech stock slump in 2023: awaiting the turnaround

Making the case for fair compensation in clinical trials

It's been 20 years since Dolly the sheep. Where's my clone?

explore

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

explore

Heart attack and stroke risk calculators need revising

Thermo Fisher plant for manufacturing gene therapies to expand

In age of alternative facts, a scholarly course on calling out crap

H5N1 bird flu outbreak: Second human case reported, in Michigan

Tori Bowie and the unacceptable rates of Black maternal death

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Experts study whether long Covid risk adds up with each reinfection

Medical leaders decry Supreme Court decision on affirmative action

Investigation reveals sickle cell patients pressured into sterilizations

leisure time

Making the case for fair compensation in clinical trials

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

ASCO eve: Let’s set the table for this year's meeting

Liver decline slowed by off

CDC's new outbreak response network to include Northeastern

As a primary care physician, here's how I hope to partner with AI

Wikipedia

Wikipedia

focus

entertainment